Please assess the completion status of the following clinical trial:

Trial Title: Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provided informed consent~2. Age 18 or older~3. History of hyperoxaluria secondary to a known underlying enteric disorder associated with malabsorption (e.g., bariatric surgery, Crohn's disease, short bowel syndrome, or other malabsorption syndrome)~4. Urinary Oxalate ≥ 50mg/24h~Exclusion Criteria:~1. Acute renal failure or estimated glomerular filtration rate (eGFR) \< 30mL/min/1.73 m2~2. Unable or unwilling to discontinue Vitamin C supplementation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALLN-177 (Type: EXPERIMENTAL): ALLN-177 3,750 units per capsule
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).